Literature DB >> 11738281

Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study.

P Verdecchia1, G Carini, A Circo, E Dovellini, E Giovannini, M Lombardo, P Solinas, M Gorini, A P Maggioni.   

Abstract

OBJECTIVES: This study investigated the prognostic value of left ventricular (LV) mass at echocardiography in uncomplicated subjects with essential hypertension.
BACKGROUND: Only a few single-center studies support the prognostic value of LV mass in uncomplicated hypertension.
METHODS: The MAssa Ventricolare sinistra nell'Ipertensione study was a multicenter (45 centers) prospective study. The prespecified aim was to explore the prognostic value of LV mass in hypertension. Admission criteria included essential hypertension, no previous cardiovascular events, and age > or =50. There was central reading of echocardiographic tracings. Treatment was tailored to the single subject.
RESULTS: Overall, 1,033 subjects (396 men) were followed for 0 to 4 years (median, 3 years). Mean age at entry was 60 years, and systolic/diastolic blood pressure was 154/92 mm Hg. The rate of cardiovascular events (x100 patient-years) was 1.3 in the group with normal LV mass and 3.2 in the group (28.5% of total sample) with LV mass > or =125 g/body surface area (p = 0.005). After adjustment for age (p < 0.01), diabetes (p < 0.01), cigarette smoking (p < 0.01) and serum creatinine (p = 0.03), LV hypertrophy was associated with an increased risk of events (RR [relative risk] 2.08; 95% CI [confidence interval]: 1.22 to 3.57). For each 39 g/m(2) (1 SD) increase in LV mass there was an independent 40% rise in the risk of major cardiovascular events (95% CI: 14 to 72; p = 0.0013).
CONCLUSIONS: Our findings show a strong, continuous and independent relationship of LV mass to subsequent cardiovascular morbidity. This is the first study to extend such demonstration to a large nationwide multicenter sample of uncomplicated subjects with essential hypertension.

Entities:  

Mesh:

Year:  2001        PMID: 11738281     DOI: 10.1016/s0735-1097(01)01663-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  78 in total

1.  Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation.

Authors:  Petri Sipola; Jarkko Magga; Minna Husso; Pertti Jääskeläinen; Keijo Peuhkurinen; Johanna Kuusisto
Journal:  Eur Radiol       Date:  2011-01-28       Impact factor: 5.315

Review 2.  Regression of left ventricular hypertrophy is a key goal of hypertension management.

Authors:  Rubin Zhang; Judy Crump; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 3.  Echocardiographic quantification of left ventricular mass: prognostic implications.

Authors:  Rajiv S Swamy; Roberto M Lang
Journal:  Curr Cardiol Rep       Date:  2010-05       Impact factor: 2.931

Review 4.  Imaging of Left Ventricular Hypertrophy: a Practical Utility for Differential Diagnosis and Assessment of Disease Severity.

Authors:  Toru Kubo; Hiroaki Kitaoka
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

5.  Accurate estimation of global and regional cardiac function by retrospectively gated multidetector row computed tomography: comparison with cine magnetic resonance imaging.

Authors:  Bénédicte Belge; Emmanuel Coche; Agnès Pasquet; Jean-Louis J Vanoverschelde; Bernhard L Gerber
Journal:  Eur Radiol       Date:  2006-03-02       Impact factor: 5.315

6.  Effect of gastrectomy on blood pressure in early gastric cancer survivors with hypertension.

Authors:  Hak Jin Kim; Eun Jeong Cho; Mi Hyang Kwak; Bang Wool Eom; Hong Man Yoon; Soo-Jeong Cho; Jong Yeul Lee; Chan Gyoo Kim; Keun Won Ryu; Young-Woo Kim; Il Ju Choi
Journal:  Support Care Cancer       Date:  2018-10-13       Impact factor: 3.603

7.  Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes.

Authors:  Yoichi Sunagawa; Tatsuya Morimoto; Tomohide Takaya; Shinji Kaichi; Hiromichi Wada; Teruhisa Kawamura; Masatoshi Fujita; Akira Shimatsu; Toru Kita; Koji Hasegawa
Journal:  J Biol Chem       Date:  2010-01-17       Impact factor: 5.157

Review 8.  Myocardial remodeling in hypertension.

Authors:  W Nadruz
Journal:  J Hum Hypertens       Date:  2014-05-08       Impact factor: 3.012

Review 9.  The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Authors:  G Neil Thomas; Paul Chan; Brian Tomlinson
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

10.  Addition of highly sensitive troponin T and N-terminal pro-B-type natriuretic peptide to electrocardiography for detection of left ventricular hypertrophy: results from the Dallas Heart Study.

Authors:  Abelardo A Martinez-Rumayor; James A de Lemos; Anand K Rohatgi; Colby R Ayers; Tiffany M Powell-Wiley; Susan G Lakoski; Jarett D Berry; Amit Khera; Sandeep R Das
Journal:  Hypertension       Date:  2012-11-12       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.